Actively Recruiting
Study of GSK5764227, a B7-H3 Antibody Drug Conjugate, Versus Topotecan in Relapsed Small Cell Lung Cancer
Led by GlaxoSmithKline · Updated on 2026-10-20
420
Participants Needed
144
Research Sites
99 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Risvutatug rezetecan Ris-Rez, a new medicine targeting specific proteins B7-H3 on cancer cells, in people with relapsed small cell lung cancer SCLC. The study compares Ris-Rez with the standard treatment topotecan to see if Ris-Rez can shrink tumors or make them disappear and if it helps participants live longer. It also examines the safety and side effects of both treatments to better understand their impact. Participants with relapsed SCLC will be randomly assigned to receive either Ris-Rez or topotecan. Both treatments will be administered according to standard protocols, with Ris-Rez provided as a biological therapy and topotecan as a drug treatment. The study is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will be monitored through various assessments including survival time, tumor response, symptom changes, brain progression, and quality of life measures. Safety will be closely tracked through adverse event reports, laboratory tests, heart function evaluations, and immune response monitoring. The main outcome focuses on overall survival, with follow-up extending up to approximately 113 weeks to capture long-term effects and responses.
CONDITIONS
Brief Title
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here